CO2024013522A2 - Composición inmunógena útil para la vacunación contra el rotavirus - Google Patents
Composición inmunógena útil para la vacunación contra el rotavirusInfo
- Publication number
- CO2024013522A2 CO2024013522A2 CONC2024/0013522A CO2024013522A CO2024013522A2 CO 2024013522 A2 CO2024013522 A2 CO 2024013522A2 CO 2024013522 A CO2024013522 A CO 2024013522A CO 2024013522 A2 CO2024013522 A2 CO 2024013522A2
- Authority
- CO
- Colombia
- Prior art keywords
- immunogenic composition
- immunogenic
- fragment
- rotavirus
- composition useful
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000702670 Rotavirus Species 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 2
- 206010067470 Rotavirus infection Diseases 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 241000282887 Suidae Species 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108700021730 rotavirus NS35 Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12351—Methods of production or purification of viral material
- C12N2720/12352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362488P | 2022-04-05 | 2022-04-05 | |
| PCT/IB2023/053433 WO2023194913A1 (en) | 2022-04-05 | 2023-04-04 | Immunogenic composition useful for vaccination against rotavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024013522A2 true CO2024013522A2 (es) | 2024-10-31 |
Family
ID=86286035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0013522A CO2024013522A2 (es) | 2022-04-05 | 2024-10-04 | Composición inmunógena útil para la vacunación contra el rotavirus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240050555A1 (https=) |
| EP (1) | EP4504251A1 (https=) |
| JP (1) | JP2025511739A (https=) |
| KR (1) | KR20240170836A (https=) |
| CN (1) | CN119894528A (https=) |
| AR (1) | AR128992A1 (https=) |
| AU (1) | AU2023251268A1 (https=) |
| CA (1) | CA3255048A1 (https=) |
| CL (1) | CL2024003001A1 (https=) |
| CO (1) | CO2024013522A2 (https=) |
| MX (1) | MX2024012371A (https=) |
| TW (1) | TW202404629A (https=) |
| WO (1) | WO2023194913A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025183704A1 (en) * | 2024-03-01 | 2025-09-04 | Vst Llc Dba Medgene | Rotavirus vaccines |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| EP0386185A1 (fr) | 1988-07-29 | 1990-09-12 | IntraCel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| ATE298370T1 (de) | 1994-04-29 | 2005-07-15 | Baxter Healthcare Sa | Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen |
| EP0871755A1 (en) | 1995-03-23 | 1998-10-21 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
| EP0979101B1 (en) | 1996-07-03 | 2010-10-27 | Merial, Inc. | Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| US6187319B1 (en) * | 1998-06-01 | 2001-02-13 | University Of Massachusetts | Cross-protective rotavirus vaccine |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US8675566B2 (en) | 2009-09-17 | 2014-03-18 | Digifonica (International) Limited | Uninterrupted transmission of internet protocol transmissions during endpoint changes |
| WO2017008049A1 (en) * | 2015-07-08 | 2017-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| CA3195910A1 (en) * | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
-
2023
- 2023-04-04 WO PCT/IB2023/053433 patent/WO2023194913A1/en not_active Ceased
- 2023-04-04 CA CA3255048A patent/CA3255048A1/en active Pending
- 2023-04-04 US US18/295,675 patent/US20240050555A1/en active Pending
- 2023-04-04 JP JP2024559187A patent/JP2025511739A/ja active Pending
- 2023-04-04 AU AU2023251268A patent/AU2023251268A1/en active Pending
- 2023-04-04 AR ARP230100839A patent/AR128992A1/es unknown
- 2023-04-04 KR KR1020247036936A patent/KR20240170836A/ko active Pending
- 2023-04-04 CN CN202380032319.XA patent/CN119894528A/zh active Pending
- 2023-04-04 EP EP23720982.0A patent/EP4504251A1/en active Pending
- 2023-04-06 TW TW112112876A patent/TW202404629A/zh unknown
-
2024
- 2024-10-04 CL CL2024003001A patent/CL2024003001A1/es unknown
- 2024-10-04 MX MX2024012371A patent/MX2024012371A/es unknown
- 2024-10-04 CO CONC2024/0013522A patent/CO2024013522A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023194913A1 (en) | 2023-10-12 |
| CN119894528A (zh) | 2025-04-25 |
| MX2024012371A (es) | 2024-11-08 |
| WO2023194913A8 (en) | 2024-01-25 |
| US20240050555A1 (en) | 2024-02-15 |
| CL2024003001A1 (es) | 2025-04-04 |
| KR20240170836A (ko) | 2024-12-04 |
| EP4504251A1 (en) | 2025-02-12 |
| AU2023251268A1 (en) | 2024-11-14 |
| CA3255048A1 (en) | 2023-10-12 |
| AR128992A1 (es) | 2024-07-03 |
| JP2025511739A (ja) | 2025-04-16 |
| TW202404629A (zh) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000836A1 (es) | Proteína de fusión útil para la vacunación contra el rotavirus | |
| ES2602971T3 (es) | Composición de anticuerpo modificado | |
| ES2600879T3 (es) | Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas | |
| MX2019005137A (es) | Vacuna contra parvovirus porcino. | |
| CO2024013522A2 (es) | Composición inmunógena útil para la vacunación contra el rotavirus | |
| ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
| AR105616A1 (es) | Proteínas de fusión | |
| MX2017005788A (es) | Vacunas terapeuticas contra el vph16. | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| AR095482A1 (es) | Virus del síndrome reproductivo y respiratorio porcino, composiciones, vacuna y métodos de uso | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| PE20131363A1 (es) | Composicion vacunal para el control de las infestaciones por ectoparasitos | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| CO2021005069A2 (es) | Vacuna de ibv h52 con proteína espicular heteróloga | |
| MX2021008035A (es) | Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña. | |
| MX2020004833A (es) | Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. | |
| MX2024008983A (es) | Polipeptidos quimericos | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| AR132053A1 (es) | Composiciones para su uso en el tratamiento de clamidia | |
| CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
| UY37448A (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus | |
| MX2020002283A (es) | Vacuna recombinante contra la enteropatia proliferativa en animales. | |
| PE20212322A1 (es) | Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos | |
| AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes | |
| Barrera Molina et al. | Inmunolocalización de la proteína VirB11 en la membrana externa de Anaplasma marginale y su reacción con sueros inmunes de bovino |